Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mylan Labs -- Ignore unavailable to you. Want to Upgrade?

To: Druggist who wrote (313)	5/19/1998 9:55:00 PM
From: David Lawrence	Read Replies (1) \| Respond to of 384

Some rare good news out of Somerset: TAMPA, Fla., May 19 /PRNewswire/ -- Somerset Pharmaceuticals, Inc. ("Somerset"), which markets Eldepryl(R) capsules for the treatment of Parkinson's disease, announced completion of its 6 week, 176 patient, Phase III multi-center clinical trial comparing its patented selegiline transdermal system (STS) with placebo therapy in patients with major depression. Analysis of the efficacy data yielded statistically significant differences between the placebo and STS treatment group when evaluating multiple efficacy endpoints. Melvin Sharoky, M.D., President of Somerset commented, "Our belief that selegiline delivered through a convenient once-a-day transdermal delivery system, would have impressive antidepressant properties is supported by a recently completed Phase III clinical trial. We are preparing to conduct the necessary clinical trials that will be needed to gain marketing approval for our product both in the U.S. and the rest of the world for major depression. We will continue our programs for additional therapeutic indications in order to maximize the value of our patents for the transdermal delivery of selegiline." This press release contains several forward-looking statements which represent the Company's expectations and beliefs concerning future events, including, but not limited to (i) the commencement, continuation and/or completion of planned clinical trials for major depression; (ii) other programs relating to additional indications; (iii) marketing approval of the drug under development by the Company from the U.S. Food and Drug Administration or other authorities; and (iv) the potential value of Somerset's patents. These forward-looking statements are qualified by important facts, risks and uncertainties that could cause actual results to differ materially from the forward-looking statements, including but not limited to, changing market conditions, clinical trial results, the impact of competitive products and pricing, the maintenance of the Company's patent portfolio and the development, FDA approval and market acceptance of the Company's products. Somerset Pharmaceuticals, Inc. is owned 50% by Watson Pharmaceuticals, Inc. (NYSE:WPI) and 50% by Mylan Laboratories, Inc. (NYSE:MYL).

To: Druggist who wrote (313)	5/19/1998 9:57:00 PM
From: David Lawrence	Respond to of 384

And, a little additional competition: POMONA, N.Y. -(Dow Jones)- Barr Laboratories Inc. has received approval from the Food and Drug Administration to market generic triamterene and hydrochlorothiazide tablets for the treatment of hypertension or edema, the company said Tuesday. The tablets, which come in 37.5-mg or 25-mg doses, are the generic equivalent of Bertek Pharmaceuticals Inc.'s Maxide's 25-mg tablets. Bertek Pharmaceuticals is a unit of Mylan Laboratories Inc. (MYL) Barr Laboratories (BRL) said it will begin shipping the generic tablets this spring. The company said the FDA approval rounds out its line of triamterene and hydrochlorothiazide products. Barr Laboratories develops, makes and markets generic and proprietary pharmaceuticals. Copyright (c) 1998 Dow Jones & Company, Inc.